3 ms·
I just read the linked Axios article, so perhaps there is more in the CDC decision, but seems like it would make the most sense to just recommend against the J&
by hn_throwaway_99 6y ago
I just read the linked Axios article, so perhaps there is more in the CDC decision, but seems like it would make the most sense to just recommend against the J&J vaccine for anyone at higher risk of clot (e.g. all 6 of the people who had clots were women of childbearing age). With 3 good vaccines available, seems like there is plenty (or shortly will be plenty) to go around even if the J&J vaccine only goes to those at low clot risk.
- sp332 6y agoI don't think the usual risk factors for clotting apply here. These cases were rare enough to stand out at just 1 per million. The clotting seems to be a specific immune response similar to some people who clot when given heparin.
- lholoubek 6y agoFWIW, the ACIP meeting today shared that another ~7 cases were discovered. In a particular group - women between 30-39 - the numbers were more like 1 in 100k. Still very small odds, but greater than the "one in a million" widely quoted, particularly for certain age groups. Good coverage of the updated data today here: https://twitter.com/kakape/status/1385661019494699010 https://twitter.com/kakape/status/1385661019494699010
- bpodgursky 6y agoGod the downvotes on this site piss me off so much. They are SO mindless. This is what the UK is doing with AstraZeneca, for the exact same problem! Only suggesting it to people over 30! Stop downvoting the suggestion which is literally expert advice!
- InitialLastName 6y agoIt's worth noting that young-to-middle-aged women are also over=represented (relative to the general public) among healthcare workers, who have been a primary target for the early rounds of vaccination.
- hn_throwaway_99 6y agoAt least where I live, none of the healthcare workers got the J&J vaccine. As you point out, they were all at the front of the line for vaccines, so they got Pfizer or Moderna before J&J was even available.